Ken Griffin Xeris Biopharma Holdings, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$2.06 - $2.96 $16,480 - $23,680	8,000 Added 9.04%	96,500 $275,000
Q2 2024 Aug 14, 2024	BUY	$1.7 - $2.45 $38,760 - $55,860	22,800 Added 34.7%	88,500 $199,000
Q1 2024 May 15, 2024	SELL	$2.04 - $3.22 $306,408 - $483,644	-150,200 Reduced 69.57%	65,700 $145,000
Q4 2023 Feb 14, 2024	SELL	$1.47 - $2.36 $55,419 - $88,972	-37,700 Reduced 14.87%	215,900 $507,000
Q3 2023 Nov 14, 2023	SELL	$1.8 - $2.69 $125,280 - $187,224	-69,600 Reduced 21.53%	253,600 $471,000
Q2 2023 Aug 14, 2023	BUY	$1.82 - $2.98 $335,062 - $548,618	184,100 Added 132.35%	323,200 $846,000
Q1 2023 May 15, 2023	SELL	$1.03 - $1.63 $53,869 - $85,249	-52,300 Reduced 27.32%	139,100 $226,000
Q4 2022 Feb 14, 2023	BUY	$1.14 - $1.65 $17,556 - $25,410	15,400 Added 8.75%	191,400 $254,000
Q3 2022 Nov 14, 2022	SELL	$1.37 - $1.93 $68,911 - $97,079	-50,300 Reduced 22.23%	176,000 $275,000

141

59.9M

148K

45.7K

Ticker XERS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,956,992
Market Cap $394M
Description
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.